Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IBR900
- Development stage
- Phase 1
- Lead developer
- Imbioray
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
IBR900 is an investigational, universal off-the-shelf natural killer (NK) cell-based immunotherapy developed by Imbioray (Hangzhou) Biomedicine Co., Ltd. It is derived from peripheral blood using a non-viral vector and non-gene edited approach, representing a "ready-to-use" cell therapy product. The drug is currently in Phase 1 clinical development for the treatment of relapsed or refractory CD20-positive B-cell non-Hodgkin lymphoma (NHL). IBR900 is designed to harness the innate anti-tumor activity of NK cells, which can identify and kill cancer cells through various activating receptors and mediate antibody-dependent cellular cytotoxicity (ADCC) when used in conjunction with monoclonal antibodies like rituximab.
- Other names
- IBR900 cell injectionIBR-900 cell injectionIBR 900 cell injection
Beyond the preview
Go deeper on IBR900.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IBR900.